Knowthestock.com
CFRX - ContraFect Corp.
We couldn't determine Recommendation based on the data we have.




Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
ContraFect Corp. (CFRX) - http://www.contrafect.com
ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.
Exchange - NASDAQ
Industry - Biotechnology
Sector - Health Technology
CEO - Roger J. Pomerantz
Employees - 24
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.